NCT06778330View on ClinicalTrials.gov

The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

NACompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions

Heart Failure NYHA Class II

Interventions

DRUG

Dapagliflozin (DAPA)

Control group: receive dapagliflozin in addition to standard therapy

DRUG

Sildenafil

Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy

Trial Locations (1)

Unknown

Fayoum University, Al Fayyum

All Listed Sponsors

lead

Fayoum University

OTHER

NCT06778330 - The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension | Biotech Hunter | Biotech Hunter